IKK-inhibitors, BMS-345541 [82] and TPCA-1 [83], counteract cell proliferation, p65 nuclear translocation, and NF-κB-regulated CXCL8 gene expression in glioma cells. The gene discussed is NFKB1; the disease is central nervous system cancer.